Literature DB >> 2815532

Prevalence of Toxoplasma gondii infection in cats in Georgia using enzyme-linked immunosorbent assays for IgM, IgG, and antigens.

M R Lappin1, C E Greene, A K Prestwood, D L Dawe, A Marks.   

Abstract

Serologic prevalence of Toxoplasma gondii infection was determined using enzyme-linked immunosorbent assays detecting immunoglobulin M (IgM), immunoglobulin G (IgG), and circulating T. gondii antigens (Ag) in 81 healthy cats and 107 cats with clinical signs referable to toxoplasmosis. A higher prevalence of infection was detected using the three assays together in healthy cats, clinically ill cats, and combined healthy and clinically ill cats than when IgG class antibody detection alone was used. IgM titers greater than or equal to 1:256 and IgG titers greater than or equal to 1:512 were present more frequently in cats with clinical signs of disease. Prevalence of present or prior infection as defined by these three assays combined increased with advancing age in both groups of cats.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2815532     DOI: 10.1016/0304-4017(89)90132-5

Source DB:  PubMed          Journal:  Vet Parasitol        ISSN: 0304-4017            Impact factor:   2.738


  4 in total

1.  Clinical management of pregnancy in cats.

Authors:  Margaret V Root Kustritz
Journal:  Theriogenology       Date:  2006-04-18       Impact factor: 2.740

2.  Clinical ocular toxoplasmosis in neonatal kittens.

Authors:  C C Powell; M R Lappin
Journal:  Vet Ophthalmol       Date:  2001-06       Impact factor: 1.644

3.  Comparison of a clinic-based ELISA test kit with the immunofluorescence antibody test for assaying Leishmania infantum antibodies in dogs.

Authors:  Daniela Proverbio; Eva Spada; Luciana Baggiani; Giada Bagnagatti De Giorgi; Roberta Perego
Journal:  Biomed Res Int       Date:  2013-09-26       Impact factor: 3.411

Review 4.  The cat with neurological manifestations of systemic disease. Key conditions impacting on the CNS.

Authors:  Marc Kent
Journal:  J Feline Med Surg       Date:  2009-05       Impact factor: 2.015

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.